Background: Meningococcal disease is a leading cause of death due to infection in children. Differences in susceptibility and disease progression between children are unknown. The complement system plays a key role in the innate immunity against N. meningitides and could explain that differences in the response of individuals. The aim of this study was to evaluate the occurrence of complement system deficiencies and MBL2 polymorphism in patients with previous meningococcal disease.
Methods: We evaluated 40 children with confirmed previous diagnosis of any form of meningococcal disease and performed quantification analysis of the complement system; C3, C4, and CH50, as well the analysis of the polymorphism of the MBL2 gene.
Results: The major deficiency was found for C4 (27.5%) followed by C3 and CH50 (2.5%). Genotyping of MBL2 showed 21 cases of homozygous wild type allele named AA, (55.3%), 14 cases heterozygous, AO (36.8%), and 3 homozygous variant alleles, OO, (7.9%).
Conclusions: Complement deficiency and polymorphism in the MBL2 gene are possible explanations for the development of meningococcal disease in some patients. Evaluation of complement could be suggested for individuals affected by this serious disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post-Program Implementation: Observational Case-Control Study.
Open Forum Infect Dis
January 2025
Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, South Australia, Australia.
Background: A 4-component meningococcal B (4CMenB) vaccine program was introduced in adolescents in 2019 in South Australia. We aimed to evaluate long-term vaccine effectiveness (VE) and impact (VI) on gonococcal infection 4 years after implementation of the program.
Methods: Disease notification data were provided by SA Health.
[Safety evaluation of tetravalent meningococcal conjugate vaccine in combination with the inactivated poliomyelitis vaccine and diphtheria-tetanus-acellular pertussis vaccine for infants].
Zhonghua Yu Fang Yi Xue Za Zhi
January 2025
Immunization Program Institute of Shaanxi Provincial Center for Disease Control and Prevention, Xi'an 710054, China.
To investigate the safety of the tetravalent meningococcal conjugate vaccine (MPCV-ACYW) in combination with the inactivated poliomyelitis (IPV) vaccine and diphtheria-tetanus-acellular pertussis (DTaP) vaccine for infants aged 3-5 months and provide real-world evidence for the immunization strategy of vaccine combination. From June to October 2023, a total of 600 3-month-old infants were selected and divided into three groups: control group, mono-vaccination group and combined vaccination group. They were simultaneously or individually vaccinated with MPCV-ACYW, IPV and DTaP vaccines at 3, 4, and 5 months of age, respectively.
View Article and Find Full Text PDFOctober 2024 ACIP Meeting Update: Influenza, COVID-19, RSV and Other Vaccines.
Pediatrics
January 2025
Department of Pediatrics, University of Cincinnati College of Medicine and Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati OH.
The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts that provides advice to the Centers for Disease Control and Prevention, normally meets 3 times per year to develop US vaccine recommendations. The ACIP met October 23-24, 2024, to discuss influenza vaccines, chikungunya vaccines, coronavirus disease (COVID-19) vaccines, RSV immunizations, meningococcal vaccines, human papillomavirus (HPV) vaccines, pneumococcal vaccines, and adult and child/adolescent immunization schedule revisions. This update summarizes the proceedings of these meetings, with an emphasis on topics that are most relevant to the pediatric population.
View Article and Find Full Text PDFImmunisation schedule of the Pediatric Spanish Association: 2024 recommendations.
An Pediatr (Engl Ed)
January 2025
Pediatrician, Barcelona, Spain.
The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties: Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age. As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age. Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10-12 years of age.
View Article and Find Full Text PDFErratum: Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2024.
Commun Dis Intell (2018)
January 2025
World Health Organisation Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, Department of Microbiology, NSW Health Pathology, The Prince of Wales Hospital, Randwick, 2031, NSW Australia.
Erratum to 2024;48. (doi: 10.33321/cdi.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!